The independent platform for news, articles and advice for professionals in laboratory medicine

Thermo Fisher Scientific opens cell therapy facility at University of California

Thermo Fisher Scientific and the University of California, San Francisco (UCSF), will accelerate advanced cell therapies for difficult to treat conditions, including cancer, rare diseases, and other illnesses, from a newly opened cGMP manufacturing facility adjacent to UCSF Medical Center’s Mission Bay campus.

The partnership between Thermo Fisher and UCSF, first announced in 2021, has the potential to demonstrate that having scientists, clinicians, and patients closer to a manufacturing site may expedite the development of breakthrough treatments. UCSF’s initial focus at the facility will be on treatments for glioblastoma, multiple myeloma, and other cancers using updated approaches to CAR-T and CRISPR technologies. Therapies for other difficult to treat conditions will follow.

“Cell therapies represent a rapidly emerging field of biotechnology with tremendous promise for future therapeutic applications,” said Michel Lagarde, Executive Vice President and Chief Operating Officer of Thermo Fisher. “With a record number of cell therapy approvals granted in the last two years, and CAR-T therapies becoming earlier treatment options, we’re in a golden age of biology, where new technologies and partnerships are evolving and transforming clinical care.”

The San Francisco facility is part of Thermo Fisher’s global pharma services network of more than 15 locations supporting cell and gene therapies. In this facility, Thermo Fisher offers UCSF, and other customers, process and analytical development capabilities, as well as clinical and commercial manufacturing services, for advanced therapies derived from either a patient’s cells or from a donor source. Customers can also benefit from Thermo Fisher’s drug development capabilities from discovery to clinical research to commercialisation.

“UCSF is one of the top clinical sites for CAR-T treatment, and our scientists are leading the next-generation of CAR-T therapy development,” said UCSF Chancellor Sam Hawgood, MBBS. “These approaches will be tested soon in patients with solid tumours like glioblastoma and later in other diseases, including autoimmunity.”

Thermo Fisher provides integrated solutions to cell therapy clients through high quality materials, services and support that accelerate workflow from discovery to clinical research and commercial manufacturing. To learn more about the company’s capabilities, please visit thermofisher.com/patheon.

 

Upcoming Events

UKMedLab23

Royal Armouries, Leeds
12-14 June 2023

Liverpool Pathology 2023

University of Liverpool
27-29 June

Microscience Microscopy Congress 2023 (mmc 2023, incorporating EMAG 2023)

Manchester Central Conference Centre
4-6 July 2023

Annual SHOT Symposium 2023

Etihad Stadium, Manchester, M11 3FF
4 July 2023

SHOT webinar: Positive patient identification for safe transfusions in adults

Online
11 July

SHOT webinar: Accurate and complete patient identification for safe transfusions in children

Online
19 July

Access the latest issue of Pathology In Practice on your mobile device together with an archive of back issues.

Download the FREE Pathology In Practice app from your device's App store

Upcoming Events

UKMedLab23

Royal Armouries, Leeds
12-14 June 2023

Liverpool Pathology 2023

University of Liverpool
27-29 June

Microscience Microscopy Congress 2023 (mmc 2023, incorporating EMAG 2023)

Manchester Central Conference Centre
4-6 July 2023

Annual SHOT Symposium 2023

Etihad Stadium, Manchester, M11 3FF
4 July 2023

SHOT webinar: Positive patient identification for safe transfusions in adults

Online
11 July

SHOT webinar: Accurate and complete patient identification for safe transfusions in children

Online
19 July

Access the latest issue of Pathology In Practice on your mobile device together with an archive of back issues.

Download the FREE Pathology In Practice app from your device's App store

Step Communications Ltd, Step House, North Farm Road, Tunbridge Wells, Kent TN2 3DR
Tel: 01892 779999 Fax: 01892 616177
www.step-communications.com
© 2023 Step Communications Ltd. Registered in England. Registration Number 3893025